This company is no longer active
Gemini Therapeutics Management
Management criteria checks 1/4
Key information
Georges Gemayel
Chief executive officer
US$717.4k
Total compensation
| CEO salary percentage | 5.34% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.2yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$43m |
| Jun 30 2022 | n/a | n/a | -US$59m |
| Mar 31 2022 | n/a | n/a | -US$68m |
| Dec 31 2021 | US$717k | US$38k | -US$72m |
Compensation vs Market: Georges's total compensation ($USD717.44K) is about average for companies of similar size in the US market ($USD749.99K).
Compensation vs Earnings: Insufficient data to compare Georges's compensation with company performance.
CEO
Georges Gemayel (62 yo)
Dr. Georges Gemayel, Ph D.,CFA, serves as Director of GlycoEra AG since July 2022. He has been Executive Chairperson of Gemini Therapeutics, Inc. since November 2021 and has been its Interim President and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim President & CEO and Executive Chairperson | less than a year | US$717.44k | no data | |
| Chief Business Officer | 1.8yrs | US$4.17m | 0% $ 0 | |
| Advisor | no data | US$10.36m | 0% $ 0 | |
| VP of Finance & Controller | 1.2yrs | no data | no data |
Experienced Management: GMTX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim President & CEO and Executive Chairperson | 1.6yrs | US$717.44k | no data | |
| Independent Director | 6.7yrs | US$78.55k | 0.040% $ 23.3k | |
| Independent Director | 2.7yrs | US$749.99k | 0% $ 0 | |
| Independent Director | 6.7yrs | US$74.67k | 0.040% $ 23.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.3yrs | US$750.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: GMTX's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/12/30 20:04 |
| End of Day Share Price | 2022/12/29 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gemini Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Graig Suvannavejh | Goldman Sachs |
| Matthew Caufield | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |